Mothers Pharmaceutical

Mothers Pharmaceutical is a South Korean pharmaceutical company founded in 2011 that specializes in the development, manufacturing, and commercialization of therapeutics for chronic and metabolic diseases. The company operates a robust contract manufacturing organization (CMO) business with GMP-certified facilities in Gyeongsan and Iksan, producing a wide range of prescription and over-the-counter medicines. Mothers Pharmaceutical is actively transitioning from a generic-focused business to an innovation-driven biopharma company, advancing its own pipeline of small molecule therapeutics. Its lead internal candidate, MTS-DA, is a RIPK1 inhibitor being developed as a non-invasive eye drop for dry age-related macular degeneration, currently in Phase 1 clinical trials. Additionally, the company is developing MTS-CP, a selective TrkA inhibitor for chronic pain, and has licensed the exclusive South Korean rights to Therapy-07, a Phase 3 topical combination therapy for androgenetic alopecia.